Current concepts in alzheimer's disease

Research output: Contribution to journalArticle

Abstract

Like my presentation, this article focuses exclusively on the role of the amyloid ß protein in Alzheimer's Disease. I first provide an overview of the research findings that have made Aß, more specifically Aß42, a compelling therapeutic target for AD that is being pursued by virtually all pharmaceutical companies. I then discuss specific approaches to Aß-centered therapy. It is widely believed that the best way to manage AD will be through preventive therapy. To implement preventive therapy, it is critically important to be able to identify normal subjects who are at imminent risk for AD. In the last part of this article, I review recent evidence indicating that the measurement of Aß40 and Aß42 in plasma may be useful for identifying those normal subjects who will develop AD.

Original languageEnglish (US)
JournalHirosaki Medical Journal
Volume61
Issue numberSUPPL.
StatePublished - Jul 8 2010

Fingerprint

Alzheimer Disease
Amyloidogenic Proteins
Therapeutics
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Current concepts in alzheimer's disease. / Younkin, Steven G.

In: Hirosaki Medical Journal, Vol. 61, No. SUPPL., 08.07.2010.

Research output: Contribution to journalArticle

@article{582dde5a7f084b13854aef140db61f32,
title = "Current concepts in alzheimer's disease",
abstract = "Like my presentation, this article focuses exclusively on the role of the amyloid {\ss} protein in Alzheimer's Disease. I first provide an overview of the research findings that have made A{\ss}, more specifically A{\ss}42, a compelling therapeutic target for AD that is being pursued by virtually all pharmaceutical companies. I then discuss specific approaches to A{\ss}-centered therapy. It is widely believed that the best way to manage AD will be through preventive therapy. To implement preventive therapy, it is critically important to be able to identify normal subjects who are at imminent risk for AD. In the last part of this article, I review recent evidence indicating that the measurement of A{\ss}40 and A{\ss}42 in plasma may be useful for identifying those normal subjects who will develop AD.",
author = "Younkin, {Steven G}",
year = "2010",
month = "7",
day = "8",
language = "English (US)",
volume = "61",
journal = "Hirosaki Medical Journal",
issn = "0439-1721",
publisher = "Hirosaki University School of Medicine",
number = "SUPPL.",

}

TY - JOUR

T1 - Current concepts in alzheimer's disease

AU - Younkin, Steven G

PY - 2010/7/8

Y1 - 2010/7/8

N2 - Like my presentation, this article focuses exclusively on the role of the amyloid ß protein in Alzheimer's Disease. I first provide an overview of the research findings that have made Aß, more specifically Aß42, a compelling therapeutic target for AD that is being pursued by virtually all pharmaceutical companies. I then discuss specific approaches to Aß-centered therapy. It is widely believed that the best way to manage AD will be through preventive therapy. To implement preventive therapy, it is critically important to be able to identify normal subjects who are at imminent risk for AD. In the last part of this article, I review recent evidence indicating that the measurement of Aß40 and Aß42 in plasma may be useful for identifying those normal subjects who will develop AD.

AB - Like my presentation, this article focuses exclusively on the role of the amyloid ß protein in Alzheimer's Disease. I first provide an overview of the research findings that have made Aß, more specifically Aß42, a compelling therapeutic target for AD that is being pursued by virtually all pharmaceutical companies. I then discuss specific approaches to Aß-centered therapy. It is widely believed that the best way to manage AD will be through preventive therapy. To implement preventive therapy, it is critically important to be able to identify normal subjects who are at imminent risk for AD. In the last part of this article, I review recent evidence indicating that the measurement of Aß40 and Aß42 in plasma may be useful for identifying those normal subjects who will develop AD.

UR - http://www.scopus.com/inward/record.url?scp=77955880509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955880509&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77955880509

VL - 61

JO - Hirosaki Medical Journal

JF - Hirosaki Medical Journal

SN - 0439-1721

IS - SUPPL.

ER -